Cargando…

Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6

BACKGROUND: Long noncoding RNAs (lncRNAs) have been identified to participate in tumorigenesis. However, the underlying mechanisms of differentially expressed lncRNAs engaged in diseases remain indistinct and need further exploration. METHODS: Raw data files downloaded from TCGA and GEO dataset were...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Mi, Luo, Chengyan, Meng, Huangyang, Li, Siyue, Nie, Sipei, Jiang, Yi, Wan, Yicong, Li, Huijian, Cheng, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875503/
https://www.ncbi.nlm.nih.gov/pubmed/31819497
http://dx.doi.org/10.2147/OTT.S227758
_version_ 1783473046122659840
author Gong, Mi
Luo, Chengyan
Meng, Huangyang
Li, Siyue
Nie, Sipei
Jiang, Yi
Wan, Yicong
Li, Huijian
Cheng, Wenjun
author_facet Gong, Mi
Luo, Chengyan
Meng, Huangyang
Li, Siyue
Nie, Sipei
Jiang, Yi
Wan, Yicong
Li, Huijian
Cheng, Wenjun
author_sort Gong, Mi
collection PubMed
description BACKGROUND: Long noncoding RNAs (lncRNAs) have been identified to participate in tumorigenesis. However, the underlying mechanisms of differentially expressed lncRNAs engaged in diseases remain indistinct and need further exploration. METHODS: Raw data files downloaded from TCGA and GEO dataset were used to analyze the differentially expressed lncRNAs and LINC00565 was picked out as the potential oncogene. qRT-PCR was used to analyze the LINC00565 level in ovarian tissues and cell lines. Subsequently, the selected ovarian tumor cells were then transfected with LINC00565 siRNA by Lipofectamine 2000 and the cell cycle was detected by flow cytometry. Effect of LINC00565 on tumor growth and cell cycle was verified by tumor formation assay in nude mice. The mechanism of LINC00565 involving in cell cycle regulation was further explored by Western blot. RESULTS: In this research, we discovered that LINC00565, a novel lncRNA, was highly expressed in ovarian cancer (OC). LINC00565 expression level was negatively associated with outcomes of OC patients. Further analysis showed that LINC00565 expression was closely correlated to tumor size, FIGO stage, but not related to other clinical features. In vitro experiments indicated that knockdown of LINC00565 significantly inhibited proliferative, invasive and migratory abilities of ovarian cancer cells. Besides, knockdown of LINC00565 can induce cell cycle arrest in G0/G1 phase. In addition, in vivo assay showed that low expression of LINC00565 inhibited the growth of OC. Further study found that LINC00565 knockdown markedly downregulated the protein expressions of CyclinD1, CyclinE1 and CDK4, but upregulated the expression of P16 and P21. Subsequently, we confirmed that LINC00565 promoted the progression of OC via upregulating GAS6, which has been confirmed to promote tumor progression. CONCLUSION: In summary, our study firstly reported that the LINC00565 functioned as an oncogene to promote the progression of OC by interacting with GAS6.
format Online
Article
Text
id pubmed-6875503
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68755032019-12-09 Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6 Gong, Mi Luo, Chengyan Meng, Huangyang Li, Siyue Nie, Sipei Jiang, Yi Wan, Yicong Li, Huijian Cheng, Wenjun Onco Targets Ther Original Research BACKGROUND: Long noncoding RNAs (lncRNAs) have been identified to participate in tumorigenesis. However, the underlying mechanisms of differentially expressed lncRNAs engaged in diseases remain indistinct and need further exploration. METHODS: Raw data files downloaded from TCGA and GEO dataset were used to analyze the differentially expressed lncRNAs and LINC00565 was picked out as the potential oncogene. qRT-PCR was used to analyze the LINC00565 level in ovarian tissues and cell lines. Subsequently, the selected ovarian tumor cells were then transfected with LINC00565 siRNA by Lipofectamine 2000 and the cell cycle was detected by flow cytometry. Effect of LINC00565 on tumor growth and cell cycle was verified by tumor formation assay in nude mice. The mechanism of LINC00565 involving in cell cycle regulation was further explored by Western blot. RESULTS: In this research, we discovered that LINC00565, a novel lncRNA, was highly expressed in ovarian cancer (OC). LINC00565 expression level was negatively associated with outcomes of OC patients. Further analysis showed that LINC00565 expression was closely correlated to tumor size, FIGO stage, but not related to other clinical features. In vitro experiments indicated that knockdown of LINC00565 significantly inhibited proliferative, invasive and migratory abilities of ovarian cancer cells. Besides, knockdown of LINC00565 can induce cell cycle arrest in G0/G1 phase. In addition, in vivo assay showed that low expression of LINC00565 inhibited the growth of OC. Further study found that LINC00565 knockdown markedly downregulated the protein expressions of CyclinD1, CyclinE1 and CDK4, but upregulated the expression of P16 and P21. Subsequently, we confirmed that LINC00565 promoted the progression of OC via upregulating GAS6, which has been confirmed to promote tumor progression. CONCLUSION: In summary, our study firstly reported that the LINC00565 functioned as an oncogene to promote the progression of OC by interacting with GAS6. Dove 2019-11-20 /pmc/articles/PMC6875503/ /pubmed/31819497 http://dx.doi.org/10.2147/OTT.S227758 Text en © 2019 Gong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gong, Mi
Luo, Chengyan
Meng, Huangyang
Li, Siyue
Nie, Sipei
Jiang, Yi
Wan, Yicong
Li, Huijian
Cheng, Wenjun
Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title_full Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title_fullStr Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title_full_unstemmed Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title_short Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
title_sort upregulated linc00565 accelerates ovarian cancer progression by targeting gas6
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875503/
https://www.ncbi.nlm.nih.gov/pubmed/31819497
http://dx.doi.org/10.2147/OTT.S227758
work_keys_str_mv AT gongmi upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT luochengyan upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT menghuangyang upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT lisiyue upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT niesipei upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT jiangyi upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT wanyicong upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT lihuijian upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6
AT chengwenjun upregulatedlinc00565acceleratesovariancancerprogressionbytargetinggas6